ClinConnect ClinConnect Logo
Search / Trial NCT05561556

Mitochondria Oxidative Stress and Vascular Health Study

Launched by AUBURN UNIVERSITY · Sep 28, 2022

Trial Information

Current as of November 08, 2025

Recruiting

Keywords

Cardiovascular Health Hypertension Health Disparities Renal Function Vascular Health

ClinConnect Summary

The Mitochondria Oxidative Stress and Vascular Health Study is looking into how a supplement called MitoQ can help improve blood vessel health and lower blood pressure, particularly in Black Americans who face higher risks of heart disease and hypertension. This research is important because cardiovascular diseases are the leading cause of death in the U.S., and Black Americans experience these health issues more severely than others. The study aims to see if MitoQ can reduce oxidative stress (which can damage cells) and improve blood pressure and blood vessel function over an 8-week period.

To participate in this study, you need to be between the ages of 45 and 75, have a blood pressure reading no higher than 150/90 mmHg, and have a body mass index (BMI) of less than 40. You should also be free from certain health conditions like diabetes or heart disease and not have any allergies to MitoQ. Participants will take either MitoQ or a placebo (a non-active version) daily and will undergo blood tests and other health assessments at the beginning and end of the study. This research not only focuses on the medication but also looks at the impact of social factors, like income and lifestyle, on health.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Are between the ages of 45-75
  • Have blood pressure no higher than 150/90 mmHg
  • Have a BMI less than 40 Kg/m2 (otherwise healthy)
  • Free from metabolic disease (diabetes or renal disease), pulmonary disorders (e.g., COPD \& cystic fibrosis), and cardiovascular disease (peripheral vascular, cardiac, or cerebrovascular)
  • Free of any medical issues that prevent participants from exercising (i.e., cardiovascular issues, or muscle/joint issues including painful arthritis), giving blood (i.e., blood thinners), or allergies associated with MitoQ substances.
  • Exclusion Criteria:
  • Known allergy to MitoQ
  • High blood pressure - greater the 150/90 mmHg
  • Low blood pressure - less than 90/50 mmHg
  • History of cardiovascular disease
  • History of cancer
  • History of diabetes
  • History of kidney disease
  • Obesity (BMI \> 40 kg/m2)
  • Current pregnancy
  • Nursing mothers
  • Communication barriers

About Auburn University

Auburn University is a leading research institution dedicated to advancing knowledge and improving health outcomes through innovative clinical trials. With a commitment to interdisciplinary collaboration, the university leverages its diverse expertise in health sciences, engineering, and social sciences to conduct rigorous research that addresses pressing healthcare challenges. Auburn University’s Clinical Trials Office ensures adherence to ethical standards and regulatory compliance, facilitating high-quality research that contributes to the scientific community and enhances patient care. Through its robust infrastructure and support services, Auburn University is poised to make significant contributions to clinical research and public health advancements.

Locations

Auburn, Alabama, United States

Patients applied

0 patients applied

Trial Officials

Austin T Robinson, PhD

Principal Investigator

Kinesiology Building

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials